About Us

About Us

As one of the portfolio drug development companies under Curyx Partners platform, Curyx Partners Therapeutics develops novel intranasal peptide therapeutics against COVID-19. Currently, because there is no treatment for COVID-19 available, developing effective therapeutic agent is of the highest importance at the moment. Furthermore, Curyx Partners Therapeutics has a number of innovative and commercially attractive assets to continue to target other coronavirus-related infectious diseases which, unfortunately, may continue to arise and spread in the future.

Curyx Partners Therapeutics is currently developing a number of intranasally administered drug compounds that are composed of relatively simple forms of peptides. Given its simple structure, our drug candidates offer substantial advantages compared to other Covid-19 treatment drugs, such as safety, patient-friendly administration, low pricing, easy handling and storage and broad application from potentially preventive measures to both early to late-stage treatment.

Our key treatment strategy is to block SARS-COV-2 virus entry into host cells through ACE2 (Angiotensin-converting enzyme 2) using CPT-101 ~ CPT-501, thereby reduce viral load in host cells significantly. In our extensive pre-clinical studies, both CPT-101 ~ CPT-501 have shown to make an intranasal safety barrier to prevent SARS-COV-2 virus from entering into host cells.